USD 13.65 billion
Atopic Dermatitis Drugs Market Size, Share, Growth Analysis, By Drug Class(Corticosteroids, Calcineurin Inhibitors, PDE4 Inhibitors, Biologics), By Route Of Administration(Topical, Injectable, Oral), By Distribution Channel(Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), By Region - Industry Forecast 2025-2032
Report ID:
SQMIG35I2166 |
Region:
Global |
Published Date: March, 2024
Pages:
219
|Tables:
62
|Figures:
75
Atopic Dermatitis Drugs Market Insights
Atopic Dermatitis Drugs Market size was valued at USD 14.91 Billion in 2023 and is poised to grow from USD 16.28 Billion in 2024 to USD 32.91 Billion by 2032, growing at a CAGR of 9.2% during the forecast period (2025-2032).
Growing incidence of atopic dermatitis around the world and increasing awareness regarding the same are forecasted to bolster the sales of atopic dermatitis drugs over the coming years. Rising spending of people on dermatological procedures and high emphasis on providing pediatric dermatology procedures are estimated to bolster the demand for atopic dermatitis drugs in the future. Advancements in drug development technologies and rising investments in R&D of novel atopic dermatitis drugs are also slated to create new opportunities for market players going forward. Topical corticosteroids, calcineurin inhibitors, immunomodulators, and biologic agents are being used extensively for the treatment of atopic dermatitis in the long run. However, high costs of biologic therapies, side effects and safety concerns, challenges in long-term management, and limited access in low to middle income companies are projected to hurt the sales of atopic dermatitis drugs on a global level through 2031 and beyond. US Atopic Dermatitis Drugs Market is poised to grow at a sustainable CAGR for the next forecast year.
Market snapshot - 2024-2031
Global Market Size
Largest Segment
Topical
Fastest Growth
Topical
Growth Rate
9.2% CAGR
Global Atopic Dermatitis Drugs Market ($ Bn)
Country Share for North America Region (%)
To get more reports on the above market click here to Buy The Report
Atopic Dermatitis Drugs Market Segmental Analysis
Global Atopic Dermatitis Drugs Market is segmented By Drug Class, By Route Of Administration, By Distribution channel and Region. Based on Drug Class, the market can be segmented into Corticosteroids, Calcineurin Inhibitors, PDE4 Inhibitors, Biologics, Others. Based on Route of Administration, the market can be segmented into Topical, Injectable, Oral. Based on Distribution Channel, the market is segmented into Hospital Pharmacies, Retail Pharmacies, Online Pharmacies. Based on region, the market is segmented into North America, Europe, Asia Pacific, Middle East and Africa, and Latin America.
Analysis by Route of Administration
Topical administration of atopic dermatitis drugs is projected to account for a significant chunk of the global atopic dermatitis drugs market share going forward. High convenience, easy availability, and high efficacy in the treatment of symptoms of atopic dermatitis are factors helping this segment maintain its dominance on a global level. High safety and tolerability by different patients are also expected to bolster the demand for topic atopic dermatitis medications in the future. Topical treatments are often used as the first line of defense against most dermatological conditions, which is also expected to favor the high share of this segment in the long run.
On the other hand, the demand for injectable atopic dermatitis drugs is forecasted to increase at a notable pace over the coming years. The growing use of novel biologic agents and immunomodulatory for the treatment of atopic dermatitis is expected to create new opportunities for atopic dermatitis drug providers focusing on this segment going forward. Surging demand for highly effective treatments for atopic dermatitis and the growing use of oral and injectable therapies in combination for faster treatment are also slated to bolster the sales of injectable atopic dermatitis drugs across the study period and beyond.
Analysis by Drug Class
Biologics are forecasted to bring in the most revenue for atopic dermatitis drugs providers in the future. Growing investments in the research and development of novel biologics and high efficacy of biologics as they target the inflammatory mechanisms are expected to aid the high atopic dermatitis drugs market share of this segment over the coming years. Rising approval of new biologics and expansion of biologic product pipeline for atopic dermatitis treatment are also further cementing the dominance of this segment through 2031 and beyond. However, biologics are mostly prescribed in severe or late-stage cases of atopic dermatitis, which limits its market share to a certain extent.
On the other hand, the use of PDE4 inhibitors for the treatment of atopic dermatitis is forecasted to increase at an impressive pace in the future. Increasing availability of atopic dermatitis drugs with PDE4 inhibitors and increasing product approvals of the same are expected to create new opportunities for atopic dermatitis drug suppliers in the long run. This type of drugs work on treating dermatological diseases by blocking the enzyme phosphodiesterase 4 (PDE4). However, side effects such as abdominal pain, headache, depression, weight loss, and nausea are expected to limit the sales of atopic dermatitis drugs utilizing PDE4 inhibitors in the long run.
Global Atopic Dermatitis Drugs Market By Route of administration
To get detailed analysis on other segments, Request For Free Sample Report
Atopic Dermatitis Drugs Market Regional Insights
The presence of leading atopic dermatitis drug providers allows North America to account for a prominent chunk of the global atopic dermatitis drugs market size in the future. High healthcare spending potential, high prevalence of dermatological diseases, and availability of favorable reimbursement policies are estimated to further cement the dominance of North American region. The United States is estimated to bring in the most revenue for atopic dermatitis drug providers looking to make a mark in this region. Rising investments in R&D of novel dermatitis treatments and frequent product approvals are also creating new opportunities for atopic dermatitis drug suppliers in North America.
Asia Pacific is forecasted to emerge as the fastest-expanding market for atopic dermatitis drugs in the world. Growing awareness regarding atopic dermatitis, rising healthcare expenditure, and increasing spending on dermatological care are forecasted to be key factors boosting sales of atopic dermatitis drugs in this region. China, Japan, and India are expected to be highly opportune markets owing to the presence of a massive population in these countries. Changing lifestyles and growing urbanization are also expected to indirectly influence the demand for atopic dermatitis drugs in this region across the forecast period and beyond.
Global Atopic Dermatitis Drugs Market By Geography
- Largest
- Fastest
To know more about the market opportunities by region and country, click here to
Buy The Complete Report
Atopic Dermatitis Drugs Market Dynamics
Atopic Dermatitis Drugs Market Drivers
High Incidence of Atopic Dermatitis
- Rising prevalence of atopic dermatitis around the world owing to changes in environment, urbanization, and genetic predisposition are expected to boost the demand for atopic dermatitis drugs over the coming years. The incidence of atopic dermatitis is slated to be especially high among children and young adults going forward.
Growing Awareness and Diagnosis
- Awareness regarding multiple dermatological conditions is increasing around the world as people become more conscious about their aesthetic and physical appearances. This has also led to higher diagnosis of atopic dermatitis thereby also boosting the sales of atopic dermatitis drugs and effective therapies for the treatment of the same.
Atopic Dermatitis Drugs Market Restraints
Side Effects and Safety Concerns
- Use of some atopic dermatitis drugs is associated with certain side effects and raises some serious concerns for long-term patient safety as well. For instance, systemic immunosuppressants used for treatment of atopic dermatitis are associated with adverse effects such as infections or liver toxicity, which result in poor quality of life for patients thereby impeding atopic dermatitis drugs market growth potential as well.
High Costs of Biologic Therapies
- Biologic atopic dermatitis drugs are often priced higher owing to their high efficacy and extensive effort involved in R&D. These high costs deter patients with limited insurance coverage and limited spending potential from opting for biologic atopic dermatitis drugs, which in turn, hurts market development going forward.
Request Free Customization of this report to help us to meet your business objectives.
Atopic Dermatitis Drugs Market Competitive Landscape
Atopic dermatitis drug suppliers should focus on expanding their business scope across multiple regions to boost sales in the future. Developing affordable yet effective biologic drugs is slated to be the prime focus of almost all atopic dermatitis drug companies going forward. Acquiring product approvals from regulatory bodies and increasing awareness regarding atopic dermatitis are also key strategies for atopic dermatitis drug providers in the long run.
Top Player’s Company Profiles
- Pfizer Inc. (US)
- Sanofi (France)
- AbbVie Inc. (US)
- GALDERMA LABORATORIES, L.P. (Switzerland)
- Eli Lilly and Company (US)
- Regeneron Pharmaceuticals Inc. (US)
- LEO Pharma Inc. (Denmark)
- Otsuka Pharmaceutical Co., Ltd. (Japan)
- Novartis AG (Switzerland)
- Incyte Corporation (US)
- Astellas Pharma Inc. (Japan)
- Bristol Myers Squibb (US)
- Johnson & Johnson (US)
- Takeda Pharmaceutical Company Limited (Japan)
- GlaxoSmithKline plc (UK)
- Boehringer Ingelheim International GmbH (Germany)
- Celgene Corporation (US)
- Meda AB (Sweden)
- Pierre Fabre Group (France)
- Bayer AG (Germany)
Recent Developments
- In September 2024, Eli Lilly and Company, a leading pharmaceutical organization announced that the United States Food and Drug Administration (FDA) approved its new treatment for atopic dermatitis. EBGLYSS™ (lebrikizumab-lbkz) was approved for use in adults and children aged 12 and above.
- In July 2024, the FDA approved a supplemental new drug application (sNDA) for ZORYVE (roflumilast) cream. The new treatment for mild to moderate atopic dermatitis is developed by Arcutis Biotherapeutics Inc. And suitable for use in patients aged 6 and above.
- In January 2024, in a collaborative effort Glenmark Pharmaceuticals and Pfizer launched an oral treatment for moderate to servere atopic dermatitis for the Indian market. Abrocitinib is being sold in India under the brand name JABRYUS and CIBINQO to improve accessibility to dermatitis treatment in the country.
Atopic Dermatitis Drugs Key Market Trends
- Use of JAK Inhibitors: Atopic dermatitis drug providers should focus on the use of JAK (Janus kinase) inhibitors to maximize their business scope in the future. rapid symptom relief and addressing unmet needs of patients affected from atopic dermatitis are benefits of using JAK inhibitors such as upadacitinib and abrocitinib. Focusing on the use of JAK inhibitors is slated to emerge as a prominent atopic dermatitis drugs market trend through 2031.
- integration of Personalized Medicine: Atopic dermatitis drug companies can target the personalized medicine approach to increase their revenue generation potential in the long run. The use of biomarkers to create individual patient profiles and create custom treatment plans is expected to present new business scope for atopic dermatitis drug providers in the long run.
Atopic Dermatitis Drugs Market SkyQuest Analysis
SkyQuest’s ABIRAW (Advanced Business Intelligence, Research & Analysis Wing) is our Business Information Services team that Collects, Collates, Correlates, and Analyses the Data collected by means of Primary Exploratory Research backed by robust Secondary Desk research.
As per SkyQuest analysis, rising prevalence of atopic dermatitis and high use of biologics for dermatitis treatment are projected to be key drivers for atopic dermatitis drugs market development going forward. On the contrary, risk of side effects and high costs of biologic therapies are estimated to impede adoption of atopic dermatitis drugs in the long run. North America is expected to spearhead the demand for atopic dermatitis drugs owing to the presence of a strong healthcare infrastructure in this region. Utilization of personalized medicine and JAK inhibitors are key atopic dermatitis drugs market trends for companies looking to expand their business in the long run.
| Report Metric | Details |
|---|---|
| Market size value in 2022 | USD 13.65 billion |
| Market size value in 2031 | USD 30.14 billion |
| Growth Rate | 9.2% |
| Base year | 2023 |
| Forecast period | 2024-2031 |
| Forecast Unit (Value) | USD Billion |
| Segments covered |
|
| Regions covered | North America (US, Canada), Europe (Germany, France, United Kingdom, Italy, Spain, Rest of Europe), Asia Pacific (China, India, Japan, Rest of Asia-Pacific), Latin America (Brazil, Rest of Latin America), Middle East & Africa (South Africa, GCC Countries, Rest of MEA) |
| Companies covered |
|
| Customization scope | Free report customization with purchase. Customization includes:-
|
To get a free trial access to our platform which is a one stop solution for all your data requirements for quicker decision making. This platform allows you to compare markets, competitors who are prominent in the market, and mega trends that are influencing the dynamics in the market. Also, get access to detailed SkyQuest exclusive matrix.
Buy The Complete Report to read the analyzed strategies adopted by the top vendors either to retain or gain market share
Table Of Content
Executive Summary
Market overview
- Exhibit: Executive Summary – Chart on Market Overview
- Exhibit: Executive Summary – Data Table on Market Overview
- Exhibit: Executive Summary – Chart on Atopic Dermatitis Drugs Market Characteristics
- Exhibit: Executive Summary – Chart on Market by Geography
- Exhibit: Executive Summary – Chart on Market Segmentation
- Exhibit: Executive Summary – Chart on Incremental Growth
- Exhibit: Executive Summary – Data Table on Incremental Growth
- Exhibit: Executive Summary – Chart on Vendor Market Positioning
Parent Market Analysis
Market overview
Market size
- Market Dynamics
- Exhibit: Impact analysis of DROC, 2021
- Drivers
- Opportunities
- Restraints
- Challenges
- Exhibit: Impact analysis of DROC, 2021
- SWOT Analysis
KEY MARKET INSIGHTS
- Technology Analysis
- (Exhibit: Data Table: Name of technology and details)
- Pricing Analysis
- (Exhibit: Data Table: Name of technology and pricing details)
- Supply Chain Analysis
- (Exhibit: Detailed Supply Chain Presentation)
- Value Chain Analysis
- (Exhibit: Detailed Value Chain Presentation)
- Ecosystem Of the Market
- Exhibit: Parent Market Ecosystem Market Analysis
- Exhibit: Market Characteristics of Parent Market
- IP Analysis
- (Exhibit: Data Table: Name of product/technology, patents filed, inventor/company name, acquiring firm)
- Trade Analysis
- (Exhibit: Data Table: Import and Export data details)
- Startup Analysis
- (Exhibit: Data Table: Emerging startups details)
- Raw Material Analysis
- (Exhibit: Data Table: Mapping of key raw materials)
- Innovation Matrix
- (Exhibit: Positioning Matrix: Mapping of new and existing technologies)
- Pipeline product Analysis
- (Exhibit: Data Table: Name of companies and pipeline products, regional mapping)
- Macroeconomic Indicators
COVID IMPACT
- Introduction
- Impact On Economy—scenario Assessment
- Exhibit: Data on GDP - Year-over-year growth 2016-2022 (%)
- Revised Market Size
- Exhibit: Data Table on Atopic Dermatitis Drugs Market size and forecast 2021-2027 ($ million)
- Impact Of COVID On Key Segments
- Exhibit: Data Table on Segment Market size and forecast 2021-2027 ($ million)
- COVID Strategies By Company
- Exhibit: Analysis on key strategies adopted by companies
MARKET DYNAMICS & OUTLOOK
- Market Dynamics
- Exhibit: Impact analysis of DROC, 2021
- Drivers
- Opportunities
- Restraints
- Challenges
- Exhibit: Impact analysis of DROC, 2021
- Regulatory Landscape
- Exhibit: Data Table on regulation from different region
- SWOT Analysis
- Porters Analysis
- Competitive rivalry
- Exhibit: Competitive rivalry Impact of key factors, 2021
- Threat of substitute products
- Exhibit: Threat of Substitute Products Impact of key factors, 2021
- Bargaining power of buyers
- Exhibit: buyers bargaining power Impact of key factors, 2021
- Threat of new entrants
- Exhibit: Threat of new entrants Impact of key factors, 2021
- Bargaining power of suppliers
- Exhibit: Threat of suppliers bargaining power Impact of key factors, 2021
- Competitive rivalry
- Skyquest special insights on future disruptions
- Political Impact
- Economic impact
- Social Impact
- Technical Impact
- Environmental Impact
- Legal Impact
Market Size by Region
- Chart on Market share by geography 2021-2027 (%)
- Data Table on Market share by geography 2021-2027(%)
- North America
- Chart on Market share by country 2021-2027 (%)
- Data Table on Market share by country 2021-2027(%)
- USA
- Exhibit: Chart on Market share 2021-2027 (%)
- Exhibit: Market size and forecast 2021-2027 ($ million)
- Canada
- Exhibit: Chart on Market share 2021-2027 (%)
- Exhibit: Market size and forecast 2021-2027 ($ million)
- Europe
- Chart on Market share by country 2021-2027 (%)
- Data Table on Market share by country 2021-2027(%)
- Germany
- Exhibit: Chart on Market share 2021-2027 (%)
- Exhibit: Market size and forecast 2021-2027 ($ million)
- Spain
- Exhibit: Chart on Market share 2021-2027 (%)
- Exhibit: Market size and forecast 2021-2027 ($ million)
- France
- Exhibit: Chart on Market share 2021-2027 (%)
- Exhibit: Market size and forecast 2021-2027 ($ million)
- UK
- Exhibit: Chart on Market share 2021-2027 (%)
- Exhibit: Market size and forecast 2021-2027 ($ million)
- Rest of Europe
- Exhibit: Chart on Market share 2021-2027 (%)
- Exhibit: Market size and forecast 2021-2027 ($ million)
- Asia Pacific
- Chart on Market share by country 2021-2027 (%)
- Data Table on Market share by country 2021-2027(%)
- China
- Exhibit: Chart on Market share 2021-2027 (%)
- Exhibit: Market size and forecast 2021-2027 ($ million)
- India
- Exhibit: Chart on Market share 2021-2027 (%)
- Exhibit: Market size and forecast 2021-2027 ($ million)
- Japan
- Exhibit: Chart on Market share 2021-2027 (%)
- Exhibit: Market size and forecast 2021-2027 ($ million)
- South Korea
- Exhibit: Chart on Market share 2021-2027 (%)
- Exhibit: Market size and forecast 2021-2027 ($ million)
- Rest of Asia Pacific
- Exhibit: Chart on Market share 2021-2027 (%)
- Exhibit: Market size and forecast 2021-2027 ($ million)
- Latin America
- Chart on Market share by country 2021-2027 (%)
- Data Table on Market share by country 2021-2027(%)
- Brazil
- Exhibit: Chart on Market share 2021-2027 (%)
- Exhibit: Market size and forecast 2021-2027 ($ million)
- Rest of South America
- Exhibit: Chart on Market share 2021-2027 (%)
- Exhibit: Market size and forecast 2021-2027 ($ million)
- Middle East & Africa (MEA)
- Chart on Market share by country 2021-2027 (%)
- Data Table on Market share by country 2021-2027(%)
- GCC Countries
- Exhibit: Chart on Market share 2021-2027 (%)
- Exhibit: Market size and forecast 2021-2027 ($ million)
- South Africa
- Exhibit: Chart on Market share 2021-2027 (%)
- Exhibit: Market size and forecast 2021-2027 ($ million)
- Rest of MEA
- Exhibit: Chart on Market share 2021-2027 (%)
- Exhibit: Market size and forecast 2021-2027 ($ million)
KEY COMPANY PROFILES
- Competitive Landscape
- Total number of companies covered
- Exhibit: companies covered in the report, 2021
- Top companies market positioning
- Exhibit: company positioning matrix, 2021
- Top companies market Share
- Exhibit: Pie chart analysis on company market share, 2021(%)
- Total number of companies covered
Methodology
For the Atopic Dermatitis Drugs Market, our research methodology involved a mixture of primary and secondary data sources. Key steps involved in the research process are listed below:
1. Information Procurement: This stage involved the procurement of Market data or related information via primary and secondary sources. The various secondary sources used included various company websites, annual reports, trade databases, and paid databases such as Hoover's, Bloomberg Business, Factiva, and Avention. Our team did 45 primary interactions Globally which included several stakeholders such as manufacturers, customers, key opinion leaders, etc. Overall, information procurement was one of the most extensive stages in our research process.
2. Information Analysis: This step involved triangulation of data through bottom-up and top-down approaches to estimate and validate the total size and future estimate of the Atopic Dermatitis Drugs Market.
3. Report Formulation: The final step entailed the placement of data points in appropriate Market spaces in an attempt to deduce viable conclusions.
4. Validation & Publishing: Validation is the most important step in the process. Validation & re-validation via an intricately designed process helped us finalize data points to be used for final calculations. The final Market estimates and forecasts were then aligned and sent to our panel of industry experts for validation of data. Once the validation was done the report was sent to our Quality Assurance team to ensure adherence to style guides, consistency & design.
Analyst Support
Customization Options
With the given market data, our dedicated team of analysts can offer you the following customization options are available for the Atopic Dermatitis Drugs Market:
Product Analysis: Product matrix, which offers a detailed comparison of the product portfolio of companies.
Regional Analysis: Further analysis of the Atopic Dermatitis Drugs Market for additional countries.
Competitive Analysis: Detailed analysis and profiling of additional Market players & comparative analysis of competitive products.
Go to Market Strategy: Find the high-growth channels to invest your marketing efforts and increase your customer base.
Innovation Mapping: Identify racial solutions and innovation, connected to deep ecosystems of innovators, start-ups, academics, and strategic partners.
Category Intelligence: Customized intelligence that is relevant to their supply Markets will enable them to make smarter sourcing decisions and improve their category management.
Public Company Transcript Analysis: To improve the investment performance by generating new alpha and making better-informed decisions.
Social Media Listening: To analyze the conversations and trends happening not just around your brand, but around your industry as a whole, and use those insights to make better Marketing decisions.
USA (+1) 351-333-4748
